Merck & Co. stock is last at USD 147.97, down 0.01 percent in New York trading
Published on 09/25/2026 at 18:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock was last at USD 147.97 in New York trading at 12:39 p.m. ET on September 25, 2026, down USD 0.01 or 0.01 percent from USD 147.98. As Merck reported on September 25, 2026, the FDA approved Welireg plus Lenvima for certain previously treated renal-cell carcinoma patients. Merck traded 0.54 percentage points below the Nasdaq Composite, which was up 0.53 percent at 12:39 p.m. ET.
The session on September 25, 2026 in figures
Merck & Co., Inc. (ISIN US58933Y1055) opened at USD 148.06 in New York trading on September 25, 2026. Merck reached a session high of USD 149.94 and a session low of USD 147.48 during the session. Merck's intraday range was USD 2.46, and the last price stood USD 8.95 below the 52-week high of USD 156.92. Merck's volume was 2,743,836 shares at 12:39 p.m. ET against an average volume of 10,094,450 shares.
Merck was last at USD 147.97 at 12:39 p.m. ET, leaving the shares between the session low and high. Merck's last price was USD 0.01 below the previous session level of USD 147.98. Merck's session movement therefore amounted to a decline of 0.01 percent at the stated time. Merck's European Tradegate quotation was EUR 129.64, down 0.34 percent at 10:47 a.m. CET on September 25, 2026.
FDA approval and analyst pressure shape the background
Merck's FDA approval covered adults with advanced renal-cell carcinoma after treatment with a PD-1 or PD-L1 inhibitor. The approval involved Welireg, Merck's belzutifan, and Lenvima, which was discovered by Eisai. The announcement added a dated regulatory development to Merck's September 25, 2026 news flow. Merck's release identified the treatment setting and the two-drug regimen.
Seeking Alpha reported on September 23, 2026 that Merck received a Hold rating in an article describing profit-taking risks after the shares reached the USD 156 area. The report characterized the action as a downgrade and cited momentum fatigue as its central argument. Merck's price remained USD 8.95 below the 52-week high at 12:39 p.m. ET. The analyst item therefore supplied a recent valuation and momentum reference.
European indexes retreat as Nasdaq advances on September 25, 2026
The DAX 40 finished at 25,256, down 0.61 percent on September 25, 2026. The Euro Stoxx 50 finished at 6,273, down 0.43 percent on the same date. Newsquawk reported the European index figures on September 25, 2026. The Nasdaq Composite stood at 27,081.99, up 142.62 points or 0.53 percent at 12:39 p.m. ET.
Merck earnings and US data set the next dates
Merck's next scheduled earnings release is October 30, 2026, according to the MarketScreener calendar. The September 30, 2026 US calendar includes third-quarter GDP data and the PCE report at 8:30 a.m. ET. VisionBoard Finance lists both releases for September 30, 2026. The data will provide fresh macro readings before Merck's October reporting date.
